FREE NEJM E-TOC    HOME   |   SUBSCRIBE   |   CURRENT ISSUE   |   PAST ISSUES   |   COLLECTIONS   |   Search Term  Advanced Search

Sign in | Get NEJM's E-Mail Table of Contents — Free | Subscribe

Previous Volume 349:1451-1464 October 9, 2003 Number 15 Next

	Since this article has no abstract, we have provided an extract of the first 100 words of the full text and any section headings.

	Full Text PDF PDA Full Text Purchase this article Add to Personal Archive Add to Citation Manager Notify a Friend E-mail When Cited E-mail When Letters Appear PubMed Citation

Chronic myeloid leukemia (CML) was probably the first form of leukemia to be recognized as a distinct entity. In 1845, two patients were described as having massive splenomegaly associated with leukocytosis,¹ which seemed to be a novel entity not explained by the other causes of splenomegaly, such as tuberculosis, that were already widely accepted in the 1840s. The first important clue to its pathogenesis came only very much later, when in 1960 newly developed techniques for studying human cells in mitosis allowed Nowell and Hungerford to detect a consistent chromosomal abnormality,² later termed the Philadelphia (Ph¹, or just Ph) . . . [Full Text of this Article]

Cytokinetics

Cytogenetics

Molecular Events

Graft-Versus-Leukemia Effect

Treatment Options

Alternatives to Transplantation

Stem-Cell Transplantation

Strategies for Decision Making

Future Prospects

Source Information

From the Department of Haematology, Faculty of Medicine, Imperial College London, London.

Address reprint requests to Dr. Goldman at Hammersmith Hospital, Imperial College London, Du Cane Rd., London W12 0NN, United Kingdom, or at jgoldman@imperial.ac.uk.

This article has been cited by other articles:

• Minagawa, K., Katayama, Y., Nishikawa, S., Yamamoto, K., Sada, A., Okamura, A., Shimoyama, M., Matsui, T. (2009). Inhibition of G1 to S Phase Progression by a Novel Zinc Finger Protein P58TFL at P-bodies. Mol Cancer Res 7: 880-889 [Abstract] [Full Text]  
• Kurosu, T., Ohki, M., Wu, N., Kagechika, H., Miura, O. (2009). Sorafenib Induces Apoptosis Specifically in Cells Expressing BCR/ABL by Inhibiting Its Kinase Activity to Activate the Intrinsic Mitochondrial Pathway. Cancer Res. 69: 3927-3936 [Abstract] [Full Text]  
• Wodarz, D. (2009). Use of oncolytic viruses for the eradication of drug-resistant cancer cells. J R Soc Interface 6: 179-186 [Abstract] [Full Text]  
• Yong, A. S. M., Keyvanfar, K., Hensel, N., Eniafe, R., Savani, B. N., Berg, M., Lundqvist, A., Adams, S., Sloand, E. M., Goldman, J. M., Childs, R., Barrett, A. J. (2009). Primitive quiescent CD34+ cells in chronic myeloid leukemia are targeted by in vitro expanded natural killer cells, which are functionally enhanced by bortezomib. Blood 113: 875-882 [Abstract] [Full Text]  
• Zhao, R., Follows, G. A., Beer, P. A., Scott, L. M., Huntly, B. J.P., Green, A. R., Alexander, D. R. (2008). Inhibition of the Bcl-xL Deamidation Pathway in Myeloproliferative Disorders. NEJM 359: 2778-2789 [Abstract] [Full Text]  
• De Weer, A., Speleman, F., Cauwelier, B., Van Roy, N., Yigit, N., Verhasselt, B., De Moerloose, B., Benoit, Y., Noens, L., Selleslag, D., Lippert, E., Struski, S., Bastard, C., De Paepe, A., Vandenberghe, P., Hagemeijer, A., Dastugue, N., Poppe, B., on behalf of the Groupe Francais de Cytogenetique, (2008). EVI1 overexpression in t(3;17) positive myeloid malignancies results from juxtaposition of EVI1 to the MSI2 locus at 17q22. haematol 93: 1903-1907 [Abstract] [Full Text]  
• Minami, Y., Stuart, S. A., Ikawa, T., Jiang, Y., Banno, A., Hunton, I. C., Young, D. J., Naoe, T., Murre, C., Jamieson, C. H. M., Wang, J. Y. J. (2008). BCR-ABL-transformed GMP as myeloid leukemic stem cells. Proc. Natl. Acad. Sci. USA 105: 17967-17972 [Abstract] [Full Text]  
• Kancha, R. K., von Bubnoff, N., Miething, C., Peschel, C., Gotze, K. S., Duyster, J. (2008). Imatinib and leptomycin B are effective in overcoming imatinib-resistance due to Bcr-Abl amplification and clonal evolution but not due to Bcr-Abl kinase domain mutation. haematol 93: 1718-1722 [Abstract] [Full Text]  
• Acquaviva, J., Chen, X., Ren, R. (2008). IRF-4 functions as a tumor suppressor in early B-cell development. Blood 112: 3798-3806 [Abstract] [Full Text]  
• Zhou, L. L., Zhao, Y., Ringrose, A., DeGeer, D., Kennah, E., Lin, A. E.-J., Sheng, G., Li, X.-J., Turhan, A., Jiang, X. (2008). AHI-1 interacts with BCR-ABL and modulates BCR-ABL transforming activity and imatinib response of CML stem/progenitor cells. JEM 205: 2657-2671 [Abstract] [Full Text]  
• Quintarelli, C., Dotti, G., De Angelis, B., Hoyos, V., Mims, M., Luciano, L., Heslop, H. E., Rooney, C. M., Pane, F., Savoldo, B. (2008). Cytotoxic T lymphocytes directed to the preferentially expressed antigen of melanoma (PRAME) target chronic myeloid leukemia. Blood 112: 1876-1885 [Abstract] [Full Text]  
• Frohling, S., Dohner, H. (2008). Chromosomal Abnormalities in Cancer. NEJM 359: 722-734 [Full Text]  
• Wu, J., Meng, F., Kong, L.-Y., Peng, Z., Ying, Y., Bornmann, W. G., Darnay, B. G., Lamothe, B., Sun, H., Talpaz, M., Donato, N. J. (2008). Association Between Imatinib-Resistant BCR-ABL Mutation-Negative Leukemia and Persistent Activation of LYN Kinase. JNCI J Natl Cancer Inst 100: 926-939 [Abstract] [Full Text]  
• Puttini, M., Redaelli, S., Moretti, L., Brussolo, S., Gunby, R. H, Mologni, L., Marchesi, E., Cleris, L., Donella-Deana, A., Drueckes, P., Sala, E., Lucchini, V., Kubbutat, M., Formelli, F., Zambon, A., Scapozza, L., Gambacorti-Passerini, C. (2008). Characterization of compound 584, an Abl kinase inhibitor with lasting effects. haematol 93: 653-661 [Abstract] [Full Text]  
• Kenealy, L. K., Christenson, C. B., Williams, C. B. (2008). Current Therapies for Chronic Myeloid Leukemia. Journal of Pharmacy Practice 21: 116-125 [Abstract]  
• Roche-Lestienne, C., Deluche, L., Corm, S., Tigaud, I., Joha, S., Philippe, N., Geffroy, S., Lai, J.-L., Nicolini, F.-E., Preudhomme, C., on behalf of the Fi-LMC group, (2008). RUNX1 DNA-binding mutations and RUNX1-PRDM16 cryptic fusions in BCR-ABL+ leukemias are frequently associated with secondary trisomy 21 and may contribute to clonal evolution and imatinib resistance. Blood 111: 3735-3741 [Abstract] [Full Text]  
• Wu, J., Meng, F., Lu, H., Kong, L., Bornmann, W., Peng, Z., Talpaz, M., Donato, N. J. (2008). Lyn regulates BCR-ABL and Gab2 tyrosine phosphorylation and c-Cbl protein stability in imatinib-resistant chronic myelogenous leukemia cells. Blood 111: 3821-3829 [Abstract] [Full Text]  
• Zhang, S.-J., Ma, L.-Y., Huang, Q.-H., Li, G., Gu, B.-W., Gao, X.-D., Shi, J.-Y., Wang, Y.-Y., Gao, L., Cai, X., Ren, R.-B., Zhu, J., Chen, Z., Chen, S.-J. (2008). Gain-of-function mutation of GATA-2 in acute myeloid transformation of chronic myeloid leukemia. Proc. Natl. Acad. Sci. USA 105: 2076-2081 [Abstract] [Full Text]  
• Marshall, H. M, Hammond, J. M (2008). Treatment Options in Imatinib-Resistant Chronic Myelogenous Leukemia. The Annals of Pharmacotherapy 42: 259-264 [Abstract] [Full Text]  
• Hochhaus, A., Druker, B., Sawyers, C., Guilhot, F., Schiffer, C. A., Cortes, J., Niederwieser, D. W., Gambacorti-Passerini, C., Stone, R. M., Goldman, J., Fischer, T., O'Brien, S. G., Reiffers, J. J., Mone, M., Krahnke, T., Talpaz, M., Kantarjian, H. M. (2008). Favorable long-term follow-up results over 6 years for response, survival, and safety with imatinib mesylate therapy in chronic-phase chronic myeloid leukemia after failure of interferon-{alpha} treatment. Blood 111: 1039-1043 [Abstract] [Full Text]  
• Jin, L., Tabe, Y., Konoplev, S., Xu, Y., Leysath, C. E., Lu, H., Kimura, S., Ohsaka, A., Rios, M.-B., Calvert, L., Kantarjian, H., Andreeff, M., Konopleva, M. (2008). CXCR4 up-regulation by imatinib induces chronic myelogenous leukemia (CML) cell migration to bone marrow stroma and promotes survival of quiescent CML cells. Molecular Cancer Therapeutics 7: 48-58 [Abstract] [Full Text]  
• Jabbour, E., Kantarjian, H. M., Abruzzo, L. V., O'Brien, S., Garcia-Manero, G., Verstovsek, S., Shan, J., Rios, M. B., Cortes, J. (2007). Chromosomal abnormalities in Philadelphia chromosome negative metaphases appearing during imatinib mesylate therapy in patients with newly diagnosed chronic myeloid leukemia in chronic phase. Blood 110: 2991-2995 [Abstract] [Full Text]  
• Gollard, R., Wierda, W., Trent, J. (2007). Chronic Myeloid Leukemia and Gastrointestinal Stromal Tumor: Simultaneous Presentation. JCO 25: 4682-4683 [Full Text]  
• Schiffer, C. A. (2007). BCR-ABL Tyrosine Kinase Inhibitors for Chronic Myelogenous Leukemia. NEJM 357: 258-265 [Full Text]  
• Yong, A. S. M., Rezvani, K., Savani, B. N., Eniafe, R., Mielke, S., Goldman, J. M., Barrett, A. J. (2007). High PR3 or ELA2 expression by CD34+ cells in advanced-phase chronic myeloid leukemia is associated with improved outcome following allogeneic stem cell transplantation and may improve PR1 peptide-driven graft-versus-leukemia effects. Blood 110: 770-775 [Abstract] [Full Text]  
• Mohty, M., Yong, A. S. M., Szydlo, R. M., Apperley, J. F., Melo, J. V. (2007). The polycomb group BMI1 gene is a molecular marker for predicting prognosis of chronic myeloid leukemia. Blood 110: 380-383 [Abstract] [Full Text]  
• Jiang, X., Saw, K. M., Eaves, A., Eaves, C. (2007). Instability of BCR-ABL Gene in Primary and Cultured Chronic Myeloid Leukemia Stem Cells. JNCI J Natl Cancer Inst 99: 680-693 [Abstract] [Full Text]  
• Michor, F. (2007). Chronic Myeloid Leukemia Blast Crisis Arises from Progenitors. Stem Cells 25: 1114-1118 [Abstract] [Full Text]  
• Miething, C., Grundler, R., Mugler, C., Brero, S., Hoepfl, J., Geigl, J., Speicher, M. R., Ottmann, O., Peschel, C., Duyster, J. (2007). Retroviral insertional mutagenesis identifies RUNX genes involved in chronic myeloid leukemia disease persistence under imatinib treatment. Proc. Natl. Acad. Sci. USA 104: 4594-4599 [Abstract] [Full Text]  
• Lerma, E. I., Nguyen, V.-A., Wang, T., Tipping, A., Melo, J. V., Kufe, D., Austin, D. J., Deisseroth, A. (2007). Novel compounds with antiproliferative activity against imatinib-resistant cell lines. Molecular Cancer Therapeutics 6: 655-666 [Abstract] [Full Text]  
• Yokota, A., Kimura, S., Masuda, S., Ashihara, E., Kuroda, J., Sato, K., Kamitsuji, Y., Kawata, E., Deguchi, Y., Urasaki, Y., Terui, Y., Ruthardt, M., Ueda, T., Hatake, K., Inui, K.-i., Maekawa, T. (2007). INNO-406, a novel BCR-ABL/Lyn dual tyrosine kinase inhibitor, suppresses the growth of Ph+ leukemia cells in the central nervous system, and cyclosporine A augments its in vivo activity. Blood 109: 306-314 [Abstract] [Full Text]  
• Campbell, P. J., Green, A. R. (2006). The Myeloproliferative Disorders. NEJM 355: 2452-2466 [Full Text]  
• Puttini, M., Coluccia, A. M. L., Boschelli, F., Cleris, L., Marchesi, E., Donella-Deana, A., Ahmed, S., Redaelli, S., Piazza, R., Magistroni, V., Andreoni, F., Scapozza, L., Formelli, F., Gambacorti-Passerini, C. (2006). In vitro and In vivo Activity of SKI-606, a Novel Src-Abl Inhibitor, against Imatinib-Resistant Bcr-Abl+ Neoplastic Cells. Cancer Res. 66: 11314-11322 [Abstract] [Full Text]  
• Jabbour, E., Cortes, J., Kantarjian, H. M., Giralt, S., Jones, D., Jones, R., Giles, F., Andersson, B. S., Champlin, R., de Lima, M. (2006). Allogeneic stem cell transplantation for patients with chronic myeloid leukemia and acute lymphocytic leukemia after Bcr-Abl kinase mutation-related imatinib failure. Blood 108: 1421-1423 [Abstract] [Full Text]  
• Griswold, I. J., MacPartlin, M., Bumm, T., Goss, V. L., O'Hare, T., Lee, K. A., Corbin, A. S., Stoffregen, E. P., Smith, C., Johnson, K., Moseson, E. M., Wood, L. J., Polakiewicz, R. D., Druker, B. J., Deininger, M. W. (2006). Kinase domain mutants of bcr-abl exhibit altered transformation potency, kinase activity, and substrate utilization, irrespective of sensitivity to imatinib.. Mol. Cell. Biol. 26: 6082-6093 [Abstract] [Full Text]  
• Rapozzi, V., Cogoi, S., Xodo, L. E. (2006). Antisense locked nucleic acids efficiently suppress BCR/ABL and induce cell growth decline and apoptosis in leukemic cells.. Molecular Cancer Therapeutics 5: 1683-1692 [Abstract] [Full Text]  
• Boissel, N., Rea, D., Tieng, V., Dulphy, N., Brun, M., Cayuela, J.-M., Rousselot, P., Tamouza, R., Le Bouteiller, P., Mahon, F.-X., Steinle, A., Charron, D., Dombret, H., Toubert, A. (2006). BCR/ABL oncogene directly controls MHC class I chain-related molecule A expression in chronic myelogenous leukemia.. J. Immunol. 176: 5108-5116 [Abstract] [Full Text]  
• Aloisi, A., Di Gregorio, S., Stagno, F., Guglielmo, P., Mannino, F., Sormani, M. P., Bruzzi, P., Gambacorti-Passerini, C., Saglio, G., Venuta, S., Giustolisi, R., Messina, A., Vigneri, P. (2006). BCR-ABL nuclear entrapment kills human CML cells: ex vivo study on 35 patients with the combination of imatinib mesylate and leptomycin B. Blood 107: 1591-1598 [Abstract] [Full Text]  
• Kimura, S., Naito, H., Segawa, H., Kuroda, J., Yuasa, T., Sato, K., Yokota, A., Kamitsuji, Y., Kawata, E., Ashihara, E., Nakaya, Y., Naruoka, H., Wakayama, T., Nasu, K., Asaki, T., Niwa, T., Hirabayashi, K., Maekawa, T. (2005). NS-187, a potent and selective dual Bcr-Abl/Lyn tyrosine kinase inhibitor, is a novel agent for imatinib-resistant leukemia. Blood 106: 3948-3954 [Abstract] [Full Text]  
• Jones, A. V., Kreil, S., Zoi, K., Waghorn, K., Curtis, C., Zhang, L., Score, J., Seear, R., Chase, A. J., Grand, F. H., White, H., Zoi, C., Loukopoulos, D., Terpos, E., Vervessou, E.-C., Schultheis, B., Emig, M., Ernst, T., Lengfelder, E., Hehlmann, R., Hochhaus, A., Oscier, D., Silver, R. T., Reiter, A., Cross, N. C. P. (2005). Widespread occurrence of the JAK2 V617F mutation in chronic myeloproliferative disorders. Blood 106: 2162-2168 [Abstract] [Full Text]  
• Haferlach, T., Kohlmann, A., Schnittger, S., Dugas, M., Hiddemann, W., Kern, W., Schoch, C. (2005). Global approach to the diagnosis of leukemia using gene expression profiling. Blood 106: 1189-1198 [Abstract] [Full Text]  
• Zhang, B., Groffen, J., Heisterkamp, N. (2005). Resistance to farnesyltransferase inhibitors in Bcr/Abl-positive lymphoblastic leukemia by increased expression of a novel ABC transporter homolog ATP11a. Blood 106: 1355-1361 [Abstract] [Full Text]  
• Komarova, N. L., Wodarz, D. (2005). Drug resistance in cancer: Principles of emergence and prevention. Proc. Natl. Acad. Sci. USA 102: 9714-9719 [Abstract] [Full Text]  
• Gannage, M., Abel, M., Michallet, A.-S., Delluc, S., Lambert, M., Giraudier, S., Kratzer, R., Niedermann, G., Saveanu, L., Guilhot, F., Camoin, L., Varet, B., Buzyn, A., Caillat-Zucman, S. (2005). Ex Vivo Characterization of Multiepitopic Tumor-Specific CD8 T Cells in Patients with Chronic Myeloid Leukemia: Implications for Vaccine Development and Adoptive Cellular Immunotherapy. J. Immunol. 174: 8210-8218 [Abstract] [Full Text]  
• Li, Z., Qiao, Y., Liu, B., Laska, E. J., Chakravarthi, P., Kulko, J. M., Bona, R. D., Fang, M., Hegde, U., Moyo, V., Tannenbaum, S. H., Menoret, A., Gaffney, J., Glynn, L., Runowicz, C. D., Srivastava, P. K. (2005). Combination of Imatinib Mesylate with Autologous Leukocyte-Derived Heat Shock Protein and Chronic Myelogenous Leukemia. Clin. Cancer Res. 11: 4460-4468 [Abstract] [Full Text]  
• Jonkers, Y M H, Claessen, S M H, Perren, A, Schmid, S, Komminoth, P, Verhofstad, A A, Hofland, L J, de Krijger, R R, Slootweg, P J, Ramaekers, F C S, Speel, E-J M (2005). Chromosomal instability predicts metastatic disease in patients with insulinomas. Endocr Relat Cancer 12: 435-447 [Abstract] [Full Text]  
• Yang, L., Lin, C., Liu, Z.-R. (2005). Phosphorylations of DEAD Box p68 RNA Helicase Are Associated with Cancer Development and Cell Proliferation. Mol Cancer Res 3: 355-363 [Abstract] [Full Text]  
• Tseng, P.-H., Lin, H.-P., Zhu, J., Chen, K.-F., Hade, E. M., Young, D. C., Byrd, J. C., Grever, M., Johnson, K., Druker, B. J., Chen, C.-S. (2005). Synergistic interactions between imatinib mesylate and the novel phosphoinositide-dependent kinase-1 inhibitor OSU-03012 in overcoming imatinib mesylate resistance. Blood 105: 4021-4027 [Abstract] [Full Text]  
• Reiter, A., Walz, C., Watmore, A., Schoch, C., Blau, I., Schlegelberger, B., Berger, U., Telford, N., Aruliah, S., Yin, J. A., Vanstraelen, D., Barker, H. F., Taylor, P. C., O'Driscoll, A., Benedetti, F., Rudolph, C., Kolb, H.-J., Hochhaus, A., Hehlmann, R., Chase, A., Cross, N. C.P. (2005). The t(8;9)(p22;p24) Is a Recurrent Abnormality in Chronic and Acute Leukemia that Fuses PCM1 to JAK2. Cancer Res. 65: 2662-2667 [Abstract] [Full Text]  
• Cebo, C., Voutsadakis, I. A., Da Rocha, S., Bourhis, J.-H., Jalil, A., Azzarone, B., Turhan, A. G., Chelbi-Alix, M., Chouaib, S., Caignard, A. (2005). Altered IFN{gamma} Signaling and Preserved Susceptibility to Activated Natural Killer Cell-Mediated Lysis of BCR/ABL Targets. Cancer Res. 65: 2914-2920 [Abstract] [Full Text]  
• Tefferi, A., Dewald, G. W., Litzow, M. L., Cortes, J., Mauro, M. J., Talpaz, M., Kantarjian, H. M. (2005). Chronic Myeloid Leukemia: Current Application of Cytogenetics and Molecular Testing for Diagnosis and Treatment. Mayo Clin Proc. 80: 390-402 [Abstract]  
• Pages, G., Pouyssegur, J. (2005). Transcriptional regulation of the Vascular Endothelial Growth Factor gene-a concert of activating factors. Cardiovasc Res 65: 564-573 [Abstract] [Full Text]  
• Koschmieder, S., Gottgens, B., Zhang, P., Iwasaki-Arai, J., Akashi, K., Kutok, J. L., Dayaram, T., Geary, K., Green, A. R., Tenen, D. G., Huettner, C. S. (2005). Inducible chronic phase of myeloid leukemia with expansion of hematopoietic stem cells in a transgenic model of BCR-ABL leukemogenesis. Blood 105: 324-334 [Abstract] [Full Text]  
• Yin, T., Wu, Y.-L., Sun, H.-P., Sun, G.-L., Du, Y.-Z., Wang, K.-K., Zhang, J., Chen, G.-Q., Chen, S.-J., Chen, Z. (2004). Combined effects of As4S4 and imatinib on chronic myeloid leukemia cells and BCR-ABL oncoprotein. Blood 104: 4219-4225 [Abstract] [Full Text]  
• Singer, C. F, Hudelist, G., Lamm, W., Mueller, R., Czerwenka, K., Kubista, E. (2004). Expression of tyrosine kinases in human malignancies as potential targets for kinase-specific inhibitors. Endocr Relat Cancer 11: 861-869 [Abstract] [Full Text]  
• Jamieson, C. H.M., Ailles, L. E., Dylla, S. J., Muijtjens, M., Jones, C., Zehnder, J. L., Gotlib, J., Li, K., Manz, M. G., Keating, A., Sawyers, C. L., Weissman, I. L. (2004). Granulocyte-Macrophage Progenitors as Candidate Leukemic Stem Cells in Blast-Crisis CML. NEJM 351: 657-667 [Abstract] [Full Text]  
• All-Ericsson, C., Girnita, L., Muller-Brunotte, A., Brodin, B., Seregard, S., Ostman, A., Larsson, O. (2004). c-Kit-Dependent Growth of Uveal Melanoma Cells: A Potential Therapeutic Target?. IOVS 45: 2075-2082 [Abstract] [Full Text]  
• Payne, S. M, Kovacs, M. J (2004). Imatinib Mesylate Treatment in Two Patients with Idiopathic Hypereosinophilic Syndrome. The Annals of Pharmacotherapy 38: 1215-1218 [Abstract] [Full Text]  
• Stork, L. (2004). TEL-AML1 and BCR-ABL: different leukemias, similar questions. Blood 103: 3611-3612 [Full Text]  
• La Rosee, P., Johnson, K., Corbin, A. S., Stoffregen, E. P., Moseson, E. M., Willis, S., Mauro, M. M., Melo, J. V., Deininger, M. W., Druker, B. J. (2004). In vitro efficacy of combined treatment depends on the underlying mechanism of resistance in imatinib-resistant Bcr-Abl-positive cell lines. Blood 103: 208-215 [Abstract] [Full Text]